Gufic Biosciences share news, announcements and annual reports
NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap
Gufic Biosciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1985 on BSE, Oct 2004 on NSE
Last close ₹423.75up ₹3.30 (0.78%)BSE ₹423.70
Share price at the NSE close on 28 Oct 2026. Previous close ₹420.45.
28 Oct: open ₹420.95, high ₹430.70, low ₹414.15
52-week range of traded prices to 28 Oct 2026
₹268.00Low, 9 Mar 2026₹467.80High, 7 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,249 Cr959th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 57.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,56,95560.7% delivered
Gufic Biosciences share news and announcements
608 announcements, routine notices left out, newest first. Page 4 of 13.
Sep 2023
1 Sep · Business
1 Sep · Board meeting
Aug 2023
29 Aug · Board meeting
11 Aug · Results
Jul 2023
Jun 2023
17 Jun · Legal
The exchange asked on 16 Jun 2023
1 Jun · Analysts
May 2023
30 May · Business
29 May · Results
23 May · Analysts
8 May · Rating
Mar 2023
29 Mar · Analysts
Feb 2023
20 Feb · Analysts
File name: “Intimationofaudiorecording”
15 Feb · Analysts
10 Feb · Management
10 Feb · Board meeting
10 Feb · Results
Dec 2022
12 Dec · Legal
Exchange has sought clarification from Gufic Biosciences Limited with respect to Financial Results dated 11-Nov-2022 for the period Sep, 2022:On the basis of aforesaid disclosure, the Listed entity is required to clarify the following:1. Consolidated: Financial Results - Not submittedThe response of the company is awaited.
Nov 2022
25 Nov · Related Party Transaction
7 Nov · Analysts
Oct 2022
12 Oct · Rating
Sep 2022
21 Sep · Analysts
3 Sep · Meeting
Aug 2022
12 Aug · Disclosure
10 Aug · Corporate action
5 Aug · Analysts
Jul 2022
Jun 2022
28 Jun · Management
24 Jun · Rating
22 Jun · Analysts